loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Linzagolix

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Linzagolix

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ObsEva Scraps Plans for Uterine Fibroid Candidate
    ObsEva Scraps Plans for Uterine Fibroid Candidate

    02 Aug 2022

    // FDANEWS

    https://www.fdanews.com/articles/208842-obseva-scraps-plans-for-uterine-fibroid-candidate?v=preview

    FDANEWS
    02 Aug 2022
    Share Share
    Women's health firm launches major reorg after ominous FDA note
    Women's health firm launches major reorg after ominous FDA note

    28 Jul 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/ominous-fda-talks-obseva-scraps-lead-womens-health-drug-plots-layoffs-major-restructuring

    Angus Liu FIERCEPHARMA
    28 Jul 2022
    Share Share
    ObsEva Announces UK MHRA Marketing Authorization for Yselty in Uterine Fibroids
    ObsEva Announces UK MHRA Marketing Authorization for Yselty in Uterine Fibroids

    28 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/28/2470795/0/en/ObsEva-Announces-UK-MHRA-Marketing-Authorization-for-Yselty-linzagolix-an-Oral-GnRH-Antagonist-for-the-Treatment-of-Uterine-Fibroids.html

    GLOBENEWSWIRE
    28 Jun 2022
    Share Share
    Theramex Announces EC Marketing Authorization for Yselty in Uterine Fibroids
    Theramex Announces EC Marketing Authorization for Yselty in Uterine Fibroids

    17 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220617005176/en

    BUSINESSWIRE
    17 Jun 2022
    Share Share
    ObsEva Presents Data on Oral GnRH Antagonist Linzagolix
    ObsEva Presents Data on Oral GnRH Antagonist Linzagolix

    25 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/25/2449884/0/en/ObsEva-Presents-Clinical-Data-on-Oral-GnRH-Antagonist-Linzagolix-at-Multiple-Congresses.html

    GLOBENEWSWIRE
    25 May 2022
    Share Share
    ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix
    ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix

    25 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/25/2427956/0/en/ObsEva-Announces-Confirmation-of-Positive-CHMP-Opinion-for-Linzagolix-an-Oral-GnRH-Antagonist-for-the-Treatment-of-Uterine-Fibroids.html

    GLOBENEWSWIRE
    25 Apr 2022
    Share Share